|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
25
|
|
pubmed:dateCreated |
2011-8-31
|
|
pubmed:abstractText |
Bortezomib has demonstrated promising activity in patients with follicular lymphoma (FL). This is the first study to evaluate the safety and efficacy of bortezomib added to rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) in previously untreated advanced-stage FL.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:BasiSanrajS,
pubmed-author:CantinGuyG,
pubmed-author:ChenBingshu EBE,
pubmed-author:CoubanStephenS,
pubmed-author:CrumpMichaelM,
pubmed-author:DjurfeldtMarinaM,
pubmed-author:GascoyneRandy DRD,
pubmed-author:ImrieKevinK,
pubmed-author:LemieuxBernardB,
pubmed-author:MacDonaldDavidD,
pubmed-author:RubinSheldonS,
pubmed-author:RubingerMorelM,
pubmed-author:SehnLaurie HLH,
pubmed-author:ShepherdLoisL,
pubmed-author:SussmanJonathanJ
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
29
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3396-401
|
|
pubmed:meshHeading |
pubmed-meshheading:21810681-Adult,
pubmed-meshheading:21810681-Aged,
pubmed-meshheading:21810681-Aged, 80 and over,
pubmed-meshheading:21810681-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:21810681-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21810681-Boronic Acids,
pubmed-meshheading:21810681-Canada,
pubmed-meshheading:21810681-Cyclophosphamide,
pubmed-meshheading:21810681-Feasibility Studies,
pubmed-meshheading:21810681-Female,
pubmed-meshheading:21810681-Follow-Up Studies,
pubmed-meshheading:21810681-Humans,
pubmed-meshheading:21810681-Lymphoma, Follicular,
pubmed-meshheading:21810681-Male,
pubmed-meshheading:21810681-Maximum Tolerated Dose,
pubmed-meshheading:21810681-Middle Aged,
pubmed-meshheading:21810681-Prednisone,
pubmed-meshheading:21810681-Pyrazines,
pubmed-meshheading:21810681-Remission Induction,
pubmed-meshheading:21810681-Survival Rate,
pubmed-meshheading:21810681-Treatment Outcome,
pubmed-meshheading:21810681-Vincristine
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group.
|
|
pubmed:affiliation |
National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada. lsehn@bccancer.bc.ca
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
